Cytokine Blood Filtration Responses in COVID-19

Shareef, Khaled Al; Bakouri, Mohsen

doi:10.1159/000508278

Cited by 35 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the context of cytokine storm syndrome (CSS) with AKI and multi-organ failure in severe COVID-19, 41,42 there is a growing interest in using cytokine filtration through the extracorporeal techniques, including the high cutoff (HCO) membrane and CytoSorb. 43 Both blood purification strategies are considered effective in reducing inflammatory cytokines (especially IL-6), 44 but whether these approaches can effectively reduce mortality and severity in patients with COVID-19 is still unknown. In the absence of established treatment options for COVID-19, experts across the globe recommended these approaches to facilitate cytokine clearance.…”

Section: Discussionmentioning

confidence: 99%

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

Pranata

Supriyadi

Huang

et al. 2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

Objective: The aim of the study was to evaluate the association between chronic kidney disease (CKD) and new onset renal replacement therapy (RRT) with the outcome of Coronavirus Disease 2019 (COVID-19) in patients. Methodology: A systematic literature search from several databases was performed on studies that assessed CKD, use of RRT, and the outcome of COVID-19. The composite of poor outcome consisted of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care, and use of mechanical ventilator. Results: Nineteen studies with a total of 7216 patients were included. CKD was associated with increased composite poor outcome (RR 2.63 [1.33, 5.17], P = .03; I2 = 51%, P = .01) and its subgroup, consisting of mortality (RR 3.47 [1.36, 8.86], P = .009; I2 = 14%, P = .32) and severe COVID-19 (RR 2.89 [0.98, 8.46], P = .05; I2 = 57%, P = .04). RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25], P < .001; I2 = 87%, P < .001), including mortality (RR 26.02 [5.01, 135.13], P < .001; I2 = 60%, P = .06), severe COVID-19 (RR 12.95 [1.93, 86.82], P = .008; I2 = 81%, P < .001), intensive care (IC) (RR 14.22 [1.76, 114.62], P < .01; I2 = 0%, P < .98), and use of mechanical ventilator (RR 34.39 [4.63, 255.51], P < .0005). Conclusion: CKD and new-onset RRT were associated with poor outcome in patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

Pranata

Supriyadi

Huang

et al. 2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

show abstract

“…Therefore, immune modulation is suggested for future options in critically ill cases. DMARDS and other immune cells' regulatory medications, such as tocilizumab and cytokine blood filtration, are presented as promising treatment options; however, their efficacy in all cases is still unclear [21,23].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in rheumatoid arthritis cases: an Iranian referral center experience

et al. 2020

View full text Add to dashboard Cite

Coronavirus infections, known as COVID-19, can induce a fatal respiratory system infection and also affect other organs, such as the kidney and heart. The mortality rate has been estimated between 1 and 5% in previous reports; however, the mortality and morbidity can be higher in patients with the immune-deficiency condition. Rheumatoid arthritis (RA) is one of the most rheumatoid disorders, and it is important to report their clinical and paraclinical data when affected with COVID-19. Evidence about their laboratory and radiologic findings is limited. In this case series, 10 cases of chronic and approved rheumatoid arthritis (RA) affected by COVID-19 are presented. Only 40% had dry cough, but myalgia and weakness as the general first presentation of infections was reported in most cases (80%). Gastrointestinal symptoms, including nausea/vomiting, diarrhea, anorexia, and abdominal pain, were reported in 50% of individuals. In blood cell count, 30% of cases had thrombocytopenia, and ESR in all cases was positive. Abnormal CRP and elevated LDH were seen in 90% of cases. In HRCT assessment, all cases had an abnormal parenchymal pattern, and 90% of cases presented the usual pattern of COVID-19 (bilateral multifocal GGO/consolidation). Although it is a limited report, these findings are helpful for comparison of clinical and paraclinical cases in RA cases with normal cases.

show abstract

“…Type-I interferon (IFN-I) activates intracellular pathogen defense and influences the development of innate immunity and adaptive immunity. The DNA sensor cyclic GMP-AMP synthase (cGAS) and the stimulator of interferon genes (STING) can control transcription of many inflammatory mediators, including type I and type III interferons [70].…”

Section: Interferonmentioning

confidence: 99%

Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review

et al. 2020

View full text Add to dashboard Cite

COVID-19 disease with a high rate of contagious and highly nonspecific symptoms, is an infectious disease caused by a newly discovered coronavirus. Most people who fall sick with COVID-19 will experience mild to moderate symptoms such as respiratory symptoms, cough, dyspnea, fever, and viral pneumonia and recover without any special cure. However, some others need special and emergency treatment to get rid of this widespread disease. Till now, there are numbers of proposed novel compounds as well as standards therapeutics agent existed for other conditions seems to have efficacy against the 2019-nCoV. Some which are being tested for MERS-CoV and SARS-CoV are validated that could be also efficient against this new coronavirus. However, there are currently no effective specific antivirals or drug combinations introduced for 2019-nCoV specifically that be supported by highlevel evidence. The main purpose of this paper is to review typical and ongoing treatments for coronavirus disease including home remedies, herbal medicine, chemical drugs, plasma therapy, and also vaccinies. In this regards, famous herbal medicines and common chemical drugs which are routinely to be prescribed for patients are introduced. Moreover, a section is assigned to the drug interactions and some outdated drugs which have been proved to be inefficient. We hope that this work could pave the way for researchers to develop faster and more reliable methods for earlier treatment of patients and rescue more people.

show abstract

Cytokine Blood Filtration Responses in COVID-19

Cited by 35 publications

References 32 publications

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

COVID-19 in rheumatoid arthritis cases: an Iranian referral center experience

Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review

Contact Info

Product

Resources

About